A

Amgen

Makes biotech medicines for serious illnesses

Business Performance Director

Full-TimePosted on 10/20/2026Deadline 10/27/26
$175.4k - $237.3k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PhD
Remote in USA
RemoteFully remote; onsite presence is required for critical workshops and planning sessions.
Project & Program ManagementProgram Management
H1B Sponsorship Available

About the job

Requirements
  • Doctorate degree and 4 years of business transformation, organizational change management, strategic planning, or program management experience; or a master's degree and 7 years of such experience; or a bachelor's degree and 9 years of such experience.
  • Experience leading change management for large business transformation programs and initiatives.
  • Expertise in sponsorship development, change communications, capability development, and behavior change.
  • Strong transformation skillset.
  • Financial acumen.
  • Project management skills.
  • Strong organizational skills, including ability to follow assignments through to completion.
  • Ability to collaborate and communicate with initiative leadership teams.
  • Strong written and oral communication, facilitation, and presentation skills.
  • Ability to work independently and interact effectively with various levels.
  • Experience operating in regulated, quality-sensitive environments; biopharma experience is preferred, with understanding of transformation delivery and business impact.
  • Ability to integrate learning, knowledge, and change management to drive sustained performance.
  • Demonstrated ability to influence a global, matrixed organization and lead enterprise change initiatives.
  • Experience designing scalable workforce processes, governance frameworks, or capability strategies.
  • Strong program and project management capability, including navigating ambiguity, driving alignment, and delivering measurable outcomes.
  • Strong written and verbal communication skills, including executive-level messaging and organizational storytelling.
Responsibilities
  • Build business cases for approval by senior executives, independently develop transformation strategies for key initiatives, and lead initiatives through the transformation process.
  • Develop value realization measures, manage the value realization process, and determine the best use of transformation tools and methods to help initiatives achieve intended outcomes.
  • Develop and implement complex change management strategies and plans related to changes to organizational structures, processes, and technologies across multiple timeframes and levels of impact.
  • Oversee others' execution of associated change-management tactics.
  • Lead senior leaders and teams through structured problem solving using the Disciplined Approach methodology to align on critical issues, options, and solutions.
  • Work across technology, process, and business functions to support solution implementation and serve as a thought partner to leaders.
  • Develop effective executive-level business cases, including financial analysis.
  • Establish initiative governance with senior leaders.
  • Manage and facilitate change teams.
  • Identify and manage interdependencies.
  • Establish realization measures and targets.
  • Develop and manage value realization plans.
  • Assess and mitigate risks to delivery and value realization.
  • Identify impacted populations and expected levels of disruption.
  • Maintain a 12-quarter plan for initiatives and programs.
  • Integrate key activities and milestones across initiatives.
  • Maintain measures that track progress and can be used in executive communications.
  • Develop and manage key milestone readiness and release readiness processes for all initiatives.
  • Lead end-to-end organizational change management for transformation programs, integrating change strategy, stakeholder engagement, communications, and training to drive adoption and sustained performance.
  • Design and execute integrated change management plans spanning process, technology, workforce, risk, and communications to drive clarity and coordinated execution.
  • Develop and execute capability frameworks that clarify roles, expectations, and leadership readiness to support successful operating model adoption.
  • Establish governance and oversee delivery of role-based learning and training programs, ensuring alignment to transformation priorities and role requirements.
  • Manage internal and external partners delivering scalable, high-quality learning experiences, including oversight of scope, deliverables, quality, and timing.
  • Establish structured communications strategies and engagement rhythms to enable transparency, alignment, and stakeholder commitment throughout the transformation lifecycle.
  • Monitor and report capability-building, training, and change metrics to inform leadership decisions and continuously improve the change approach.
  • Standardize and scale capability enablement processes to ensure consistency, efficiency, and sustainability across the organization.
Desired Qualifications
  • Experience operating in regulated, quality-sensitive environments, preferably biopharma.
  • Experience designing scalable workforce processes, governance frameworks, or capability strategies.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.